Dr. Mengchao Cui is a professor and doctoral supervisor at Beijing Normal University, and the director of the Key Laboratory of Radiopharmaceuticals of the Ministry of Education. 

Professor Cui Mengchao has long been engaged in the research and development of molecular probes targeting β-amyloid plaque (Aβ) and Tau protein aggregates in the brain of patients with Alzheimer's disease (AD), and a number of new drugs have been reviewed by ethics committees of many hospitals, and hundreds of human imaging studies have been completed, among which the positron emission tomography diagnostic drug targeting Aβ [18F]florbetazine has obtained the phase I clinical approval of a new drug in China.